Current status and impact of CMV prevention following pediatric organ transplantation

Pediatric Transplantation

Volumn 12, Issue 4, 2008, Pages 389-392

  Allen, Upton D ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; IMMUNOGLOBULIN; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; CELLULAR IMMUNITY; CHILD; CYTOMEGALOVIRUS INFECTION; EDITORIAL; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PATIENT MONITORING; RECIPIENT; RISK FACTOR; T LYMPHOCYTE; VIRUS LOAD;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MANAGEMENT; GANCICLOVIR; GRAFT REJECTION; HUMANS; IMMUNE SYSTEM; LYMPHOPROLIFERATIVE DISORDERS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION;

EID: 43249093083     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00984.x     Document Type: Editorial

References (37)

1. Fishman J. Infection in solid organ transplant recipients. N Engl J Med 2007 : 327 : 2601 2614.
2. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989 : 261 : 3607 3609.
3. Griffiths PD, Whitley RJ, eds. Recommendations from the IHMF Management Strategies Workshop and 8th Annual Meeting of the International Herpes Management Forum. The challenge of CMV infection and disease in transplantation, November 11, 2000. Worthing United Kingdom : Cambridge Medial Publications. Available at http://www.ihmf.org/library/monograph/m_1.pdf Accessed February 2008.
4. Kranz B, Vester U, Wingen A-M, et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 2008 : 12 : 474 478.
5. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Inf Dis 2002 : 34 : 1094 1097.
6. Preiksaitis JK, Brennan D, Fishman J, Allen U. Canadian Society of Transplantation Consensus Workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005 : 5 : 218 227.
7. Boeckh M, Boivin G. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications. Clin Microbiol Rev 1998 : 11 : 533 554.
8. Singh N. Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: Are we winning the battle only to lose the war? Eur J Clin Microbiol Infect Dis 2002 : 21 : 543 646.
9. Sester M, Gärtner BC, Sester U, Girndt N, Mueller-Lanrtzsch N, Kohler H. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity Transplantation 2003 : 76 : 1229 1230.
10. Ter Meulen CG, Wetzels JFM, Hilbrands L. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 2000 : 15 : 711 714.
11. Sarmiento JM, Dockrell DH, Schwab TR, et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000 : 14 : 136 138. doi :.
12. Robinson LG, Hilinski J, Graham F, et al. Predictors of cytomegalovirus disease among pediatric transplant recipients within one year of renal transplantation. Pediatr Transplant 2002 : 6 : 111 118.
13. Giral M, Nguyen JM, Daguin P, et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol 2001 : 12 : 1758 1763.
14. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989 : 261 : 3561 3566.
15. Loebe M, Schuler S, Zais O, et al. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant 1990 : 9 : 707 711.
16. Everett JP, Hershberger RE, Norman DJ, et al. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant 1992 : 11 : S133 S137.
17. Bando K, Paradis IL, Komatsu K, et al. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg 1995 : 109 : 49 57.
18. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994 : 344 : 1737 1738.
19. Bouedjoro-Camus MC, Novella JL, Toupance O, et al. Cytomegalovirus infection, a risk factor for acute graft rejection in renal transplant recipients. A case-controlled study. Presse Med 1999 : 28 : 619 624.
20. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999 : 340 : 1462 1470.
21. Gane E, Saliba F, Valdecasas GJ, et al. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus in liver transplant recipients. Lancet 1997 : 350 : 1729 1733. Erratum Lancet 1998: 351: 454.
22. Radovancevic B, Poindexter S, Birovljev S, et al. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Surg 1990 : 4 : 309 312.
23. Sharples LD, Caine N, Mullins P, et al. Risk factor analysis for the major hazards following heart transplantation - rejection, infection, and coronary occlusive disease. Transplantation 1991 : 52 : 244 252.
24. Weimar W, Balk AH, Metselaar HJ, Mochtar B, Rothbarth PH. On the relation between cytomegalovirus infection and rejection after heart transplantation. Transplantation 1991 : 52 : 162 164.
25. Paya CV, Wiesner RH, Hermans PE, et al. Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation. Hepatology 1992 : 16 : 66 70.
26. van den Berg AP, Klompmaker IJ, Hepkema BG, et al. Cytomegalovirus infection does not increase the risk of vanishing bile duct syndrome after liver transplantation. Transpl Int 1996 : 9 (Suppl. 1 S171 S173.
27. Reischig T, Jindra P, Hes O, Švecová M, Klaboch J, Třeška V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008 : 8 : 69 77.
28. Singh N, Wannstedt C, Keys L, et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transplant 2008 : 14 : 240 244.
29. Levitsky J, Singh N, Wagener MM, Storsor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008 : 8 : 158 161.
30. Danziger-Isakov LA, Faro A, Sweet S, et al. Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: Survey of eight pediatric lung transplant programs. Pediatr Transplant 2003 : 7 : 312 313.
31. Limaye AP. Antiviral resistance in CMV: An emerging problem in organ transplant recipients. Sem Resp Infect 2002 : 17 : 265 273.
32. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005 : 49 : 873 883.
33. Infectious Diseases Community of Practice, American Society of Transplantation. Guidelines for the prevention and management of infectious complications of solid organ transplantation: Cytomegalovirus. Am J Transplant 2004 : 4 (Suppl. 10 51 58.
34. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis. Clin Transplant 2008 : 22 : 89 97.
35. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999 : 39 : 800 804.
36. Bouw R, Vaudry W, Walker R, Ettenger RB, Jara P, Varela-Fascinetto G on Behalf of the WV16726 Study Group. Ganciclovir pharmacokinetics in pediatric solid organ transplant recipients after administration of valganciclovir oral solution: Abstract# 442. World Transplant Congress 2006. Am J Transplant 2006 : 6 (Suppl. 2 215.
37. Vethamuthu V, Feber J, Chretien A, Lampe D, Filler G. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant 2007 : 11 : 301 305.